Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: Br J Haematol. 2011 Aug 25;155(2):150–166. doi: 10.1111/j.1365-2141.2011.08852.x

Table 4.

Summary of histone deactylase inhibitors and specificity to a particular class of HDAC.

HDAC Class
I IIA IIB IV
HDACi 1 2 3 8 4 5 7 9 6 10 11 Diseases studied
Vorinostat + + + + + + + + + + + 29.7% RR in CTCL (Olsen et al 2007b) FDA approved in CTCL
Panobinostat + + + + + + + + + + + 40% OOR in phase I and 21% phase II in HL (Buglio & Younes 2010). Currently in trials for PTCL
Belinostat + + + + + + + + + + + 0 complete response, 5 stable disease in phase I in haematological malignancies (Gimsing et al 2008) Currently phase III PTCL
NVP-LAQ824 + + + + + + + + + + + 3/39 stable disease in treated solid tumours (De Bono et al 2008). In trial for multiple myeloma
Depsipeptide + + + + 34% RR in CTCL (Whittaker et al 2010). Approved CTCL
Entinostat + + Solid tumours 2/27 partial responses (Gore et al 2008). Currently phase II in Hodgkin lymphoma
Mocetinostat + + + − − − − + Phase I: 3/23 complete responses in leukaemia (Garcia-Manero et al 2008b)

HDAC, histone deactylase; HDACi, histone deactylase inhibitors; CTCL, Cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma;FDA, US Food and Drug Administration.